At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 59 enrolled
Drug / intervention
antisense oligonucleotide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Participant, Investigator and Sponsor Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intrathecally Administered NIO752 in Participants With Progressive Supranuclear Palsy
In Brief
A Phase 1 clinical trial evaluating antisense oligonucleotide and placebo for Progressive Supranuclear Palsy (PSP). Completed, enrolled 59 participants across 12 sites in 4 countries.
Detailed Summary
This is a phase 1, multi-center, double-blind, placebo-controlled, multiple dose escalation study with NIO752 in progressive supranuclear palsy (PSP) participants.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProgressive Supranuclear Palsy (PSP)
CountriesCanada, Germany, United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedSep 2020
Enrollment StartFeb 2021
Primary CompletionOct 2024
TodayJul 2026
First PostedSep 4, 2020
Enrollment StartFeb 16, 2021
Primary CompletionOct 17, 2024
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 5.8 years ago
Interventions
antisense oligonucleotidedrug
solution of antisense oligonucleotide injected intrathecally (spine tap) at multiple dose levels
placebodrug
placebo for each dose level